If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
59
results.
Updated on
05/11/2025 [07:37:00]
Results 25 to 50 of 59
Absstract of: US2025306039A1
Provided are methods of phospho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, and treatment. Novel p-tau sites, p-tau198, p-tauS356, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.
Absstract of: WO2025208162A1
Methods of differentiating and quantifying modifications in the tau protein in bio-fluids to detect, classify, and treat a plurality of tauopathies are disclosed. The disclosed methods include liquid chromatographic mass spectrometric analyses on isolated tau protein fragments to identify and quantify deamidated or isomerized asparagines or aspartic acids indicative of a neuropathology associated with a tauopathy.
Absstract of: US2025306037A1
The present disclosure relates to methods useful to identify subjects having an increased risk for conversion to mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and/or stage a subject prior to the onset of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and/or identify subjects with Aβ amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aβ amyloidosis, as well as methods for treating subjects diagnosed with Aβ amyloidosis by the methods disclosed herein.
Absstract of: CN120559249A
The present invention provides compounds and methods for targeting human tau, particularly human tau phosphorylated at threonine 217 and tau isoforms expressed only in CNS, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications for use in the field of neurodegenerative diseases such as AD, PSP and FTD.
Absstract of: WO2024166074A1
The present invention relates to a method of isolating exosomes from human immature dental pulp stem cell (hIDPSC) cultures that is scalable. The present invention also provides pharmaceutical compositions comprising exosomes and methods of using these pharmaceutical compositions to treat a neurological disease or condition, infectious disease, or cancer.
Absstract of: US2024197682A1
A method of inhibiting propagation of protein misfolding associated with a neurological disease, is carried out by contacting an environment populated with a propagating amyloid conformation of a protein (prion) associated with a neurological disease with molecules which binds multiple adjacent sites of the protein assemblies and allowing the molecules to bind multiple cites of the protein assemblies; and thereby impeding propagation of the disease-associated conformation of the protein in the environment. Drug/prion complexes are formed and uses of the drugs in detection and treatment of neurodegenerative diseases are disclosed.
Absstract of: WO2024194276A1
The present invention is directed to methods for determining the level of PAM and/or its isoforms and/or fragments thereof in a bodily fluid or a tissue sample using an assay, wherein said assay is comprising at least one binder that is directed to a conformational epitope of PAM, and its use for diagnostic purpose.
Absstract of: NZ750096A
A method of detecting the presence of alpha-synuclein aggregation in a biological sample is provided whereby a biological sample is mixed with a reaction sample comprising a population of beads, a fluorophore adapted to bind to protein aggregates and to increase fluorescence when bound to protein aggregates, and alpha-synuclein or a fragment or variant thereof to form a reaction mixture, the reaction mixture is illuminated and at the same time incubated with intermittent agitation cycles, wherein a significant increase in the fluorescence of the reaction mixture during incubation is indicative of the presence of aggregates of alpha-synuclein in the biological sample. Method of diagnosing alpha-synucleinopathies such as Parkinson’s disease or Dementia with Lewy Bodies.
Absstract of: AU2025226659A1
The present disclosure provides methods for blood-based examination useful to identify subjects with Aβ amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aβ amyloidosis, as well as methods for treating subjects diagnosed with Aβ amyloidosis by the methods disclosed herein. The present disclosure provides methods for blood-based examination useful to identify subjects with Aß amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aß amyloidosis, as well as methods for treating subjects diagnosed with Aß amyloidosis by the methods disclosed herein. ep h e p r e s e n t d i s c l o s u r e p r o v i d e s m e t h o d s f o r b l o o d - b a s e d e x a m i n a t i o n u s e f u l t o e p i d e n t i f y s u b j e c t s w i t h ß a m y l o i d o s i s a n d o r t o i d e n t i f y s u b j e c t s w h o s h o u l d o r s h o u l d n o t u n d e r g o f u r t h e r t e s t i n g o r t r e a t m e n t f o r ß a m y l o i d o s i s , a s w e l l a s m e t h o d s f o r t r e a t i n g s u b j e c t s d i a g n o s e d w i t h ß a m y l o i d o s i s b y t h e m e t h o d s d i s c l o s e d h e r e i n
Absstract of: WO2025199015A1
This invention provides skin cell fibroblast- and blood-based methods for determining whether a human subject has a gene expression profile characteristic of AD. This invention also provides related methods for determining whether a demented human subject is afflicted with AD or non-ADD, and for determining whether a non-demented human subject has an increased likelihood of becoming afflicted with AD.
Absstract of: AU2025226709A1
The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody. The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody. ep e p h e p r e s e n t i n v e n t i o n r e l a t e s t o a n a n t i - a l p h a - s y n u c l e i n a n t i b o d y p r e f e r e n t i a l l y r e c o g n i z i n g a l p h a - s y n u c l e i n a g g r e g a t e s a n d a u s e o f d e t e c t i o n , d i a g n o s i s , a n d o r t r e a t m e n t o r p r e v e n t i o n o f v a r i o u s d i s e a s e s c a u s e d b y a c c u m u l a t i o n o f a l p h a - s y n u c l e i n a g g r e g a t e s , o r t h e i r r e l a t e d s y m p t o m d i s e a s e s b y u s i n g t h e a n t i - a l p h a - s y n u c l e i n a n t i b o d y
Absstract of: US2025296997A1
The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
Absstract of: US2025298039A1
This disclosure relates to methods for diagnosing and treating a tauopathy, e.g., Alzheimer's disease, in a subject, the methods comprising, in part, identifying one or more post-translation modifications (PTMs) in the subject.
Absstract of: WO2025199451A2
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive or quality-of-life function.
Absstract of: US2025295643A1
In various aspects and embodiments the invention provides a method of treating epilepsy in a subject in need thereof, the method comprising providing to the subject an effective amount of an FLNA modulator. In various embodiments, the FLNA modulator is PTI-125 or kartogenin. In various embodiments, the epilepsy is epilepsy associated with focal cortical dysplasia (FCD) type II or tuberous sclerosis complex (TSC).
Absstract of: US2025298023A1
A method for diagnosing neurodegenerative diseases, the method including measuring the JNK3 levels in a biological sample selected from plasma, CSF, and saliva. The method also includes measuring P-JNK3.
Absstract of: WO2025199495A1
The present invention provides methods and compositions for reducing internalization and/or trafficking of tan in neuronal cells comprising contacting the cells with an effective amount of VLDL receptor antagonist. The invention further provides a method of treating or preventing Alzheimer's disease in a subject in need thereof, comprising administering to the subject an effective amount of a VLDL receptor antagonist.
Absstract of: WO2024107948A1
A process for determining an extent of a central nervous system (CNS) specific neurological condition in a subject including collecting a biological sample of biofluid from the subject and measuring a quantity of a first biomarker, or metabolite of or mRNA corresponding to, the first biomarker from the sample from a dried spot or through a microfluidic device. The biofluid is capillary blood or saliva, which affords ease of collection advantages that are attractive for field-, hospital-, and home-based environments. The process being useful in the diagnosis, care, and management of brain specific abnormal neurological conditions in general, and in particular, to traumatic brain injury (TBI) and (TBI-induced) Alzheimer's disease (AD) and Alexander disease, in which a GFAP mutation is implicated in white matter deterioration.
Absstract of: US2025277799A1
Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.
Absstract of: US2025290037A1
Modified cells that express and present or secrete at least one therapeutic molecule that can treat or ameliorate a disease of interest such as but not limited to Alzheimer's disease. In the modified cells, expression of the therapeutic molecule is induced when the modified cells are proximate to or in contact with pathology related to the disease of interest. The present disclosure also relates to compositions and kits comprising the disclosed cells. The present disclosure also relates to methods of using the disclosed cells for treating disease.
Absstract of: US2025289874A1
The present application belongs to the technical field of biomedicine, and more particularly, relates to an antibody or an antigen-binding fragment thereof capable of specifically binding to p-tau 217, and a multi-specific molecule, a pharmaceutical composition, and a kit comprising same. The present application further relates to use of the antibody or antigen-binding fragment thereof in preparing a kit or a drug. A monoclonal antibody (for example, 2A7 antibody) according to the present application has a high clinical application value in the detection and prevention of AD and the treatment of AD and other tau protein diseases.
Absstract of: WO2025190329A1
Anti-Aβ drug screening targets and a drug screening method. The screening method uses different Aβ aggregates prepared by simulating the in vivo environment and conditions as targets, to more accurately and effectively screen anti-Aβ candidate drugs; the Aβ targets involved in the screening method are aggregated and incubated under conditions approaching different in vivo microenvironments, and do not require labeling or modification; in addition, the screened drug molecules do not require any modification or labeling, and are not limited to any specific drug class, being widely applicable to different drug types, such as antibodies, peptides and small molecules, truly reflecting the interactions between targets and these drug molecules, greatly reducing the likelihood of problems such as false positives, false negatives or incorrect binding modes.
Absstract of: WO2025192800A1
The present invention relates to a pharmaceutical composition for preventing or treating Alzheimer's disease, the composition comprising, as an active ingredient, neural crest-derived nasal turbinate stem cells (NTSCs) expressing SSEA3 and CD105. Treatment with the NTSCs expressing SSEA3 and CD105 or with an NTSC cell line including at least a predetermined proportion of the NTSCs was found to result in remarkably good therapeutic activity against Alzheimer's disease. Therefore, the present invention is expected to be effectively used not only as a composition for preventing or treating Alzheimer's disease in which the composition includes, as an active ingredient, NTSCs expressing SSEA3 and CD105 or an NTSC cell line including at least a predetermined proportion of the NTSCs, but also for uses such as screening of NTSC formulations that can be used to treat Alzheimer's disease, or prediction of the therapeutic efficacy thereof.
Absstract of: US2025290935A1
Provided in the present application is a marker of Alzheimer's disease, which marker comprises monocyte chemoattractant protein-1 (MCP 1). Further provided in the present application are a method for detecting the marker of Alzheimer's disease, a kit for detecting Alzheimer's disease, and the use of the marker, the detection method and the kit in the screening of a drug for treating Alzheimer's disease.
Nº publicación: JP2025134876A 17/09/2025
Applicant:
ユニバーシティオブテネシーリサーチファウンデーション
Absstract of: US2024294620A1
Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.
BOPI
Electronic site
